KARACHI: Liven Pharma Limited reported a notable improvement in its financial performance for the quarter ended March 31, 2026, with revenue almost doubling year-on-year while significantly reducing its net loss, reflecting stronger sales growth despite ongoing operational challenges.
According to the company’s condensed interim financial statements, quarterly revenue surged to Rs. 29.25 million, compared with Rs. 14.76 million in the corresponding period last year. The strong top-line growth also helped lift gross profit to Rs. 8.42 million, more than double the Rs. 3.74 million recorded a year earlier.
Despite the higher revenue, Liven Pharma continued to face elevated administrative and operating expenses, resulting in an operating loss of Rs. 5.53 million. However, this represented an improvement from the Rs. 7.31 million operating loss reported in the same quarter of the previous year.
The company’s net loss after tax narrowed to Rs. 3.96 million, compared with a loss of Rs. 9.62 million in the corresponding quarter last year. Likewise, loss per share improved to Rs. 0.03, down from Rs. 0.10 per share a year earlier.
In its directors’ report, the company noted that Pakistan’s pharmaceutical industry remained resilient during the quarter, supported by sustained demand for essential healthcare products. However, the sector continued to grapple with challenges including regulatory pricing restrictions, imported raw material dependence, exchange rate fluctuations, and supply chain pressures.
Management stated that it remains focused on improving operational efficiency, controlling costs, and strengthening revenue streams to support sustainable growth. The board also expressed confidence in the company’s future prospects while acknowledging the need to carefully manage operational and financial risks.
During the reporting period, the company also completed the credit of its right shares through the Central Depository Company (CDC), increasing its paid-up share capital to 113.04 million ordinary shares. No dividend was announced for the quarter, and the company reported no material events after the reporting date requiring adjustment or disclosure.
